Definitive Healthcare Corp. (DH)
| Market Cap | 139.05M -76.1% |
| Revenue (ttm) | 232.70M -5.0% |
| Net Income | -168.20M |
| EPS | -1.61 |
| Shares Out | 144.84M |
| PE Ratio | n/a |
| Forward PE | 5.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,566,143 |
| Open | 0.9300 |
| Previous Close | 0.9582 |
| Day's Range | 0.9300 - 0.9910 |
| 52-Week Range | 0.6103 - 4.3500 |
| Beta | 1.40 |
| Analysts | Hold |
| Price Target | 2.13 (+121.88%) |
| Earnings Date | Nov 5, 2026 |
About DH
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution. The company’s platform consists of various functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician... [Read more]
Financial Performance
In 2025, Definitive Healthcare's revenue was $241.52 million, a decrease of -4.24% compared to the previous year's $252.20 million. Losses were -$138.93 million, -66.37% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for DH stock is "Hold." The 12-month stock price target is $2.13, which is an increase of 121.88% from the latest price.
News
Definitive Healthcare moved to No Rating at BofA
BofA moved to No Rating on Definitive Health after the company announced its board received a nonbinding indication of interest from Advent International to acquire all of the outstanding shares…
Definitive Healthcare confirms going-private proposal from Advent International
The special committee of the board of directors of Definitive Healthcare (DH) announced that it has received a non-binding indication of interest from Advent International on behalf of certain of…
Special Committee of Definitive Healthcare Board Confirms Receipt of Going-Private Proposal from Advent International
FRAMINGHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- The special committee (the “Special Committee”) of the Board of Directors of Definitive Healthcare Corp. (the “Company”) (Nasdaq: DH), an industry...
Definitive Healthcare CEO Kevin Coop departs, Clay Ritchey succeeds
Definitive Healthcare (DH) announced that its board of directors has appointed Clay Ritchey as the company’s next CEO and as a member of the board of directors, each effective September…
Definitive Healthcare Appoints Clay Ritchey as CEO
FRAMINGHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced th...
Definitive Healthcare price target lowered to $1 from $3 at Deutsche Bank
Deutsche Bank analyst George Hill lowered the firm’s price target on Definitive Healthcare (DH) to $1 from $3 and keeps a Hold rating on the shares.
Definitive Healthcare price target lowered to $1.50 from $2.50 at Morgan Stanley
Morgan Stanley analyst Craig Hettenbach lowered the firm’s price target on Definitive Healthcare (DH) to $1.50 from $2.50 and keeps an Equal Weight rating on the shares. The firm, which…
Definitive Healthcare Earnings Call Transcript: Q2 2026
Q2 2026 results met or exceeded guidance, with revenue down 9% year-over-year and strong profitability. Strategic investments in AI, data, and digital activation are driving customer retention and new wins, while the Turbo platform is expected to support future growth.
Definitive Healthcare Slides: Q2 2026
Definitive Healthcare has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 10, 2026.
Definitive Healthcare Earnings release: Q2 2026
Definitive Healthcare released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Definitive Healthcare Quarterly report: Q2 2026
Definitive Healthcare has published its Q2 2026 quarterly earnings report on August 10, 2026.
Definitive Healthcare raises FY26 adjusted EPS view to 18c-20c from 16c-19c
Consensus 18c. Narrows FY26 revenue view to $220M from $220M-$226M, consensus $223.45M. Sees FY26 adjusted EBITDA view $57M-$59M.
Definitive Healthcare reports Q2 adjusted EPS 5c, consensus 4c
Reports Q2 revenue $55.2M, consensus $55.39M. “Definitive Healthcare (DH) delivered another quarter in line with or above our guidance ranges, reflecting continued discipline alongside targeted invest...
Definitive Healthcare sees Q3 adjusted EPS 4c-5c, consensus 4c
Sees Q3 revenue $54M-$55M, consensus $55.38M. Sees Q3 adjusted EBITDA $13.5M-$14.5M.
Definitive Healthcare Launches Early Adopter Program for New AI-Powered Healthcare Intelligence Platform
Unifying claims, provider, consumer, and expert data enables organizations to uncover growth opportunities and make faster, better-informed decisions Unifying claims, provider, consumer, and expert da...
Definitive Healthcare Announces Timing of Its Second Quarter 2026 Financial Results Conference Call and Webcast
FRAMINGHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced tha...
Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
FRAMINGHAM, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of...
Definitive Healthcare downgraded to Underperform from Buy at BofA
BofA downgraded Definitive Healthcare (DH) to Underperform from Buy with a price target of 70c, down from $3.50. While shares are currently “cheap” and cash flow is positive, the firm…
Restaurant365 Names Kate Hastings Chief Customer Officer as It Expands Investment in Customer Success
Customer success leader joins executive team to help restaurant operators accelerate value realization, adoption, and business outcomes. IRVINE, Calif.
Definitive Healthcare advances data platform and integrations to deliver smarter healthcare insights
Latest enhancements provide deeper medical claims insights, a new integration with HubSpot®, seamless access to healthcare professional (HCP) data directly in Salesforce, and AI search capabilities La...
Definitive Healthcare price target lowered to $1.10 from $1.30 at Baird
Baird lowered the firm’s price target on Definitive Healthcare (DH) to $1.10 from $1.30 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results.
Definitive Healthcare reports Q1 adjusted EPS 6c, consensus 3c
Reports Q1 revenue $55.93M, consensus $54.98M. “Definitive Healthcare (DH) started 2026 on a solid note, with financial results at or above the high end of our guidance ranges. We continue…
Definitive Healthcare sees Q2 adjusted EPS 3c-4c, consensus 4c
Sees Q2 revenue $55M-$56M, consensus $55.47M.
Definitive Healthcare raises FY26 adjusted EPS view to 16c-19c from 14c-17c
Consensus 17c. Backs FY26 revenue view $220M-$226M, consensus $223.64M. Backs FY26 adjusted EBITDA view $13.5M-$14.5M.
Definitive Healthcare Earnings Call Transcript: Q1 2026
Q1 2026 results were at or above guidance, with revenue down 6% year-over-year and strong margin expansion. Provider and diversified segments grew, offsetting life sciences declines, while AI and integration investments are expected to drive future growth.